Advanced Nanoplatform Mediated by CRISPR-Cas9 and Aggregation-Induced Emission Photosensitizers to Boost Cancer Theranostics

• Published in: ACS nano 2024-12, Vol.18 (48), p.33168-33180
• Main Authors: Wang, Yuanwei, Chen, Penghang, Wen, Haifei, Gui, Yixiong, Yan, Dingyuan, Huang, Di, Wang, Dong, Tang, Ben Zhong, Tan, Hui
• Format: Article
• Language: English
• Subjects: Animals; Antineoplastic Agents - chemistry; Antineoplastic Agents - pharmacology; Cell Line, Tumor; Cell Proliferation - drug effects; CRISPR-Cas Systems - genetics; Drug Screening Assays, Antitumor; Humans; Immunotherapy; Mice; Mice, Inbred BALB C; Nanoparticles - chemistry; Neoplasms - diagnostic imaging; Neoplasms - genetics; Neoplasms - pathology; Neoplasms - therapy; Photosensitizing Agents - chemistry; Photosensitizing Agents - pharmacology; Reactive Oxygen Species - metabolism; Theranostic Nanomedicine
• ISSN: 1936-0851; 1936-086X; 1936-086X
• DOI: 10.1021/acsnano.4c11757

Immunotherapy combined with phototherapy is emerging as a promising strategy to treat omnipotent cancers. In this study, a clustered regularly interspaced short palindromic repeats (CRISPR)-associated protein 9 (Cas9) system, aggregation-induced emission (AIE) photosensitizer (PS) and surface coating of polyethylene imine/hyaluronic acid were combined to construct a multifunctional nanoplatform, denoted as TCPH nanoparticles (NPs), for comprehensive cancer theranostics. TCPH NPs are featured by intrinsic functions including efficient reactive oxygen species (ROS) production, good photothermal conversion, programmed death-ligand 1 (PD-L1)-eliminating capability, and effective intracellular transport. The generated ROS and hyperthermia do not only achieve primary tumor elimination but also regulate the tumor immune microenvironment. Genomic disruption of PD-L1 conspicuously augments its therapeutic efficacy, especially in tumor metastasis and recurrence. Exceptional multimodal imaging navigation has also been developed. Excellent theranostics performance was substantiated in diverse tumor models, implying that this synergistic strategy of phototheranostics and immunotherapy provides a paradigm shift in emerging CRISPR-mediated nanomedicines.